Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
EMV.AX
Strong SellEMVision Medical Devices Ltd · Healthcare · Australia · $111M · Avg Vol: $37K/d
COMPANY DESCRIPTION
EMVision Medical Devices Ltd is a medical technology company developing portable, non-invasive electromagnetic microwave imaging devices for rapid stroke and brain injury diagnosis. The company's competitive moat is established through its proprietary algorithms and hardware that enable point-of-care brain imaging, bypassing the need for bulky MRI or CT scanners. This innovative technology positions EMVision as a pioneer in the multi-billion-dollar emergency neuroimaging market.
FINANCIAL SUMMARY (AUD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | 5.5M | 5.0M | — |
| EPS (AUD) | -0.08 | -0.05 | -0.03 | -0.11 | — | -0.09 | -0.10 | -0.11 | — |
| Shares | 77.6M | 77.9M | 85.4M | 85.5M | +10.2% | 93.0M | — | — | — |
| Debt | 0.7M | 3.0M | 2.9M | 3.5M | 68.6% | 3.4M | — | — | — |
| Equity | 7.1M | 5.1M | 18.5M | 9.3M | 9.4% | — | — | — | — |
| Op CF | -3.8M | 0.8M | -6.0M | -7.8M | — | -6.3M | — | — | — |
| Inv CF | -0.2M | -0.2M | -0.3M | -50.4K | — | — | — | — | — |
| Fin CF | 1.1M | 2.5M | 15.0M | -0.3M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of EMV.AX are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| EMV.AX | EMVision Medical Devices Ltd(you) | $111M | 14 | Strong Sell |
| COV.AX | Cleo Diagnostics Ltd | $54M | 6 | Strong Sell |
| SOM.AX | SomnoMed Limited | $53M | 27 | Sell |
| PNV.AX | PolyNovo Limited | $515M | 33 | Sell |
| AVR.AX | Anteris Technologies Global Corp. | $861M | 26 | Sell |
| 4DX.AX | 4DMedical Limited | $1.6B | 11 | Strong Sell |
| ACW.AX | Actinogen Medical Limited | $118M | 18 | Strong Sell |
| DXB.AX | Dimerix Limited | $118M | 9 | Strong Sell |
| NYR.AX | Nyrada Inc. | $147M | 13 | Strong Sell |
| OCC.AX | Orthocell Limited | $147M | 14 | Strong Sell |
Peer medians: ROE -20.6% · P/E 34.6x · Gross margin 61.1%